Most emerging biotech companies to watch

1. VOL-10 | ISSUE-02 | 2022 Most The10 Emerging Emerging Emerging Biotech Companies To Watch in 2022 Jeff Aronin, Chairman Evozyne E Ev vo oz zy yn ne e Engineering Biology to Solve Societal Challenges www.insightssuccess.com

2. The cure to life is Biotechnology Way to save the life of every individual.

3. The cure to life is Biotechnology Way to save the life of every individual.

4. Editor’s Desk iotechnology has become a major engine for enabled biotech to scale its progress, stimulate innovation national and urban competitiveness in the twenty- for patients and created financial success for investors and B first century. Biotechnology is being explored as a founders. crucial development for future advancements and growing competition for policymakers. To further succeed in the niche, emerging companies try to create an "end-to-end" entity from research and It has always been a knowledge-driven sector because of its development to commercialization, bringing their consistency in comprehensively working to create value, product(s) to market themselves. Moreover, ensuring the decoding genomics and proteomics and being a R&D profile continues to be the focus of most other biotech paradigmatic knowledge-based economic activity. companies' attention remains a primary aim for these Biotechnology industries are also among the most biotech companies. innovative and important economic drivers in the modern business world. Among those who are R&D-focused, some adopt a Embarking on "diversify approach," resulting in a significant increase in However, the biotechnology market has raised expectations the number of assets across multiple therapeutic areas and among investors, workers, and consumers. This is partly relying heavily on revenue generated through collaboration related to the COVID-19 pandemic, which motivated the the Prospects agreements to advance assets past pre-clinical and Phase 1 acceleration in investments in the sector so commonly stages. characterized by its long-term results. Biotech industry trends have revolved around diversifying the production of Embracing the ascending odyssey of the starlets that are patents and investing a lot of capital without expecting to Foster enabling transformations in the biotech industry, Insights short and mid-term results—a typical script regarding the Success features the triumph trail of "The 10 Most sector that could hold onto investors. Emerging Biotech Companies to Watch in 2022.” Eventually, this requires considering how they can scale up Bio-Innovations Flip through the pages and read on to comprehend the and what is required, in order to deliver on their promise of immersive advancements that are being driven by a vision providing innovative medicines to patients. Early in the life to empower limitless ennoblements in the global healthcare cycle, a biotech company's management team typically industry. grows the business through a few core assets and limited programmers, focusing its resources where the most value Have a Delightful Read! can be gained, such as differentiation in manufacturing, understanding of disease and biology, or drug chemistry. One of the important aspects that have been significantly contributing to core drivers of longer-term success is building a portfolio of products to sustain growth – this research seeks to identify which portfolio approaches have Abhishek Joshi Abhishek Joshi

5. Editor’s Desk iotechnology has become a major engine for enabled biotech to scale its progress, stimulate innovation national and urban competitiveness in the twenty- for patients and created financial success for investors and B first century. Biotechnology is being explored as a founders. crucial development for future advancements and growing competition for policymakers. To further succeed in the niche, emerging companies try to create an "end-to-end" entity from research and It has always been a knowledge-driven sector because of its development to commercialization, bringing their consistency in comprehensively working to create value, product(s) to market themselves. Moreover, ensuring the decoding genomics and proteomics and being a R&D profile continues to be the focus of most other biotech paradigmatic knowledge-based economic activity. companies' attention remains a primary aim for these Biotechnology industries are also among the most biotech companies. innovative and important economic drivers in the modern business world. Among those who are R&D-focused, some adopt a Embarking on "diversify approach," resulting in a significant increase in However, the biotechnology market has raised expectations the number of assets across multiple therapeutic areas and among investors, workers, and consumers. This is partly relying heavily on revenue generated through collaboration related to the COVID-19 pandemic, which motivated the the Prospects agreements to advance assets past pre-clinical and Phase 1 acceleration in investments in the sector so commonly stages. characterized by its long-term results. Biotech industry trends have revolved around diversifying the production of Embracing the ascending odyssey of the starlets that are patents and investing a lot of capital without expecting to Foster enabling transformations in the biotech industry, Insights short and mid-term results—a typical script regarding the Success features the triumph trail of "The 10 Most sector that could hold onto investors. Emerging Biotech Companies to Watch in 2022.” Eventually, this requires considering how they can scale up Bio-Innovations Flip through the pages and read on to comprehend the and what is required, in order to deliver on their promise of immersive advancements that are being driven by a vision providing innovative medicines to patients. Early in the life to empower limitless ennoblements in the global healthcare cycle, a biotech company's management team typically industry. grows the business through a few core assets and limited programmers, focusing its resources where the most value Have a Delightful Read! can be gained, such as differentiation in manufacturing, understanding of disease and biology, or drug chemistry. One of the important aspects that have been significantly contributing to core drivers of longer-term success is building a portfolio of products to sustain growth – this research seeks to identify which portfolio approaches have Abhishek Joshi Abhishek Joshi

6. 22 28 08 Evozyne Evozyne Engineering Biology to Solve Societal Challenges 32 36 Golden Helex Providing Leading Genomic Data Analysis Software Cover Story 38 40 16 20 26

7. 22 28 08 Evozyne Evozyne Engineering Biology to Solve Societal Challenges 32 36 Golden Helex Providing Leading Genomic Data Analysis Software Cover Story 38 40 16 20 26

8. Most The10 Emerging Emerging Emerging Editor-in-Chief Marry D'Souza Biotech Biotech Biotech Managing Editor Executive Editor Assistant Editors Companies Abhishek Joshi Jenny Fernandes Anish Miller To Watch in 2022 Art & Design Director Associate Designer Visualizer David King Revati Badkas Sandeep Tikode Company Name Featured Person Brief Senior Sales Manager Business Development Manager 3Scan is turning tissue biology and histopathology into data Kshitij S Peter Collins 3Scan Todd Hulman, science, giving researchers the insights they need to break new 3scan.com CEO & Co-founder ground. Marketing Manager Sales Executives ClinCapture is revolutionizing the clinical trial industry with John Matthew David, Martin Scott Weidley, ClinCapture c Virtual Data Capture® and is the only provider of VDC®, a President & CEO lincapture.com leading-edge suite of products designed to expedite remote and decentralized clinical trials. Technical Head Business Development Executives CMIC is an innovative and unique provider of high-quality Jenny Lin, CMIC Inc solutions for the healthcare industry. Jacob Smile Steve, Joe COO & Board of Director en.cmicgroup.com We create value by accelerating the access to therapies that improve patients’ lives. Evozyne combines evolution and deep learning technology to Technical Specialist Digital Marketing Manager create highly functional novel proteins — Natural Machines™ Evozyne Jeff Aronin, Dominique T. Amar Sawant — to solve longstanding challenges in therapeutics and evozyne.com Chairman sustainability. Golden Helix has been delivering industry-leading Research Analyst SME-SMO Executive Golden Helixh Andreas Scherer, bioinformatics solutions for over 20 years with 1,000s of users Frank Adams Renuka Kulkarni goldenhelix.com President & CEO around the world. Janrain is the first choice of global enterprises for mission- Janrain Jim Kaskade, critical customer identity and access management (CIAM) Database Management Technology Consultant Circulation Manager janrain.com CEO needs. Stella Andrew David Stokes Robert Brown Metrendalytics Consulting, focused on helping companies sales@insightssuccess.com Metrendalytics Jan Miotto, develop highly customized and flexible business intelligence metrendalytics.com October, 2022 President solutions. The organization aims to deliver excellent clinical development Peachtree BioResearch Sharon Hilton, services and innovative resourcing solutions that let our clients Solutions COO & Kristy Nichols, complete their clinical trials in an efficient and cost-effective Follow us on : www.facebook.com/insightssuccess/ www.twitter.com/insightssuccess peachtreebrs.com CEO manner. We are also available on : Triox Nano Ltd(Israel) is an innovative bio-technology Copyright © 2022 Insights Success, All rights reserved. The content and images used in this magazine should not be reproduced or transmitted in any Roy Farfara, company developing programmable biologic nano carriers that form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights Success. Triox Nano Founder & CTO Reprint rights remain solely with Insights Success. are able to accurately deliver payloads to their target.

9. Most The10 Emerging Emerging Emerging Editor-in-Chief Marry D'Souza Biotech Biotech Biotech Managing Editor Executive Editor Assistant Editors Companies Abhishek Joshi Jenny Fernandes Anish Miller To Watch in 2022 Art & Design Director Associate Designer Visualizer David King Revati Badkas Sandeep Tikode Company Name Featured Person Brief Senior Sales Manager Business Development Manager 3Scan is turning tissue biology and histopathology into data Kshitij S Peter Collins 3Scan Todd Hulman, science, giving researchers the insights they need to break new 3scan.com CEO & Co-founder ground. Marketing Manager Sales Executives ClinCapture is revolutionizing the clinical trial industry with John Matthew David, Martin Scott Weidley, ClinCapture c Virtual Data Capture® and is the only provider of VDC®, a President & CEO lincapture.com leading-edge suite of products designed to expedite remote and decentralized clinical trials. Technical Head Business Development Executives CMIC is an innovative and unique provider of high-quality Jenny Lin, CMIC Inc solutions for the healthcare industry. Jacob Smile Steve, Joe COO & Board of Director en.cmicgroup.com We create value by accelerating the access to therapies that improve patients’ lives. Evozyne combines evolution and deep learning technology to Technical Specialist Digital Marketing Manager create highly functional novel proteins — Natural Machines™ Evozyne Jeff Aronin, Dominique T. Amar Sawant — to solve longstanding challenges in therapeutics and evozyne.com Chairman sustainability. Golden Helix has been delivering industry-leading Research Analyst SME-SMO Executive Golden Helixh Andreas Scherer, bioinformatics solutions for over 20 years with 1,000s of users Frank Adams Renuka Kulkarni goldenhelix.com President & CEO around the world. Janrain is the first choice of global enterprises for mission- Janrain Jim Kaskade, critical customer identity and access management (CIAM) Database Management Technology Consultant Circulation Manager janrain.com CEO needs. Stella Andrew David Stokes Robert Brown Metrendalytics Consulting, focused on helping companies sales@insightssuccess.com Metrendalytics Jan Miotto, develop highly customized and flexible business intelligence metrendalytics.com October, 2022 President solutions. The organization aims to deliver excellent clinical development Peachtree BioResearch Sharon Hilton, services and innovative resourcing solutions that let our clients Solutions COO & Kristy Nichols, complete their clinical trials in an efficient and cost-effective Follow us on : www.facebook.com/insightssuccess/ www.twitter.com/insightssuccess peachtreebrs.com CEO manner. We are also available on : Triox Nano Ltd(Israel) is an innovative bio-technology Copyright © 2022 Insights Success, All rights reserved. The content and images used in this magazine should not be reproduced or transmitted in any Roy Farfara, company developing programmable biologic nano carriers that form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights Success. Triox Nano Founder & CTO Reprint rights remain solely with Insights Success. are able to accurately deliver payloads to their target.

10. C o v e r S t o r y E Ev vo oz zy yn ne e Engineering Biology to Solve Societal Challenges If nature is the world's best engineer, imagine what it can do if it's fast-forwarded by a few million years. -Jeff Aronin, Chairman, Evozyne

11. C o v e r S t o r y E Ev vo oz zy yn ne e Engineering Biology to Solve Societal Challenges If nature is the world's best engineer, imagine what it can do if it's fast-forwarded by a few million years. -Jeff Aronin, Chairman, Evozyne

12. The 10 Most Emerging Biotech Companies To Watch in 2022 echnical advancements in genetics and build-up of phenylalanine when a person eats protein or supercomputing are driving an astonishing amount foods containing aspartame, which severely alters their T of scientific progress, colloquially known as the quality of life. biology revolution. The advances come at a fortuitous time. Environmental threats are chipping away at the quality of Evozyne delivered an engineered enzyme that greatly life for millions, while new viral illnesses continue to exceeded Takeda's design specifications, which led to an emerge and thousands of known diseases lack effective initial multi-asset licensing agreement worth up to $400 treatments. million plus potential royalties from any commercial product resulting from the collaboration. Our technology Evozyne, founded by Paragon Biosciences, was created outperformed expectations in this critical test and resulted on the premise that the new-found ability to create high- in an important collaboration for both companies. We are performance proteins can deliver solutions to the some of hopeful this partnership with Takeda will lead to new most intractable modern problems. The company believes treatments that significantly improve the quality of life for that by learning from evolution, it is possible to engineer patients. future-proofed interventions for patients and address environmental challenges in carbon capture and energy What are the primary objectives and philosophy of storage. Evozyne? To learn more about its biology-based advancements, we at We believe boundary-breaking biology is the key to Insights Success crossed paths with Evozyne's team, and in transformational applications in therapeutics and the following interview, the company outlines its sustainability. Understanding that nature is the original and pathbreaking vision to benefit humanity. best engineer, we use deep evolutionary learning in the lab to understand millions of years of evolution. Below are the highlights of the interview. By using evolution-based design, we're able to tackle some What was the initial idea behind the inception of of society's biggest challenges, like finding treatments for Evozyne? patients with untreated diseases and developing solutions for sustainability concerns. Evozyne was founded by Paragon Biosciences to advance boundary-breaking biology from the laboratory and into the Philosophically, we are highly pragmatic and our design- therapeutics. From a timeline point of function in the conditions real world, where it can solve complex problems. build-test approach is applied to every aspect of our work. view, Evozyne works from the earliest points, associated with power generation. Believing that the engineered proteins will dramatically We partner with like-minded entities, working together to identifying and optimizing lead targets, and continues its accelerate scientific breakthroughs, in two years we find world-changing solutions. work through developing experimental therapeutics and Our tests indicate that we have a product that meets the recruited a world-class team of nearly 100 computational supporting them through Phase 3 clinical trials. challenge of enzymatic on-site carbon capture, which scientists, researchers, and commercial leaders to conduct a To realize the impact and potential of our engineered means if successful the CO from power generation is never series of validation projects from Evozyne's new 30,000- proteins, we need partners who share our vision for a better 2 Currently, we are creating high-performance enzymes for released into the atmosphere. We look forward to proving square-foot lab in Chicago. world and a commitment to the breakthrough approaches our partners at Takeda and developing antibody, gene its performance, first at the University of Kentucky this year required to get there. Our next-generation proteins can be optimization, and CRISPR technology platforms that we and later at the National Carbon Capture Center in Evozyne's evolution-based design is about encapsulating tailored across functions, and our efficient design-build-test believe will lead to the development of breakthrough Alabama. vital information from the evolutionary history of a protein cycles enable commercial-scale solutions that unlock new therapeutics for patients. into a computationally defined latent space that enables products and IP for our partners. What are the roadblocks that Evozyne faces in the ever- rational design of natural-like proteins. When combined On the sustainability side, protein engineering moves the changing landscape of the business world? with an iterative design-build-test approach, the models What are your key offerings that have a foothold in the science beyond traditional chemical catalysts by developing generate protein designs that far exceed performance of industry? enzymes that can withstand industrial conditions, Science is unpredictable, and it's hard. Those two facts, plus natural proteins and can be deployed in in real-world functioning in high-temperature conditions, and the competitive nature of biotech businesses, make it applications. Evozyne began by combining artificial intelligence, overcoming pH resistance. tempting to rush products to market. There are notable specifically machine learning, with applied biology to examples of synthetic biology companies that gave in to In an early project, Evozyne partnered with Takeda, the accelerate scientific discovery. The process speeds up lead Our lead sustainability candidate is engineered to perform that temptation, sold products that didn't perform as billed Japanese pharmaceutical company, to improve the identification for new medicines, which can result in at temperatures above 260 degrees Fahrenheit in an and subsequently failed. therapeutic potential of a specific target to treat a severe findings that support investigational new drug applications industrial setting. Until now, no enzyme has been able to genetic disease. This inherited disorder causes a dangerous and biologic license applications for experimental

13. The 10 Most Emerging Biotech Companies To Watch in 2022 echnical advancements in genetics and build-up of phenylalanine when a person eats protein or supercomputing are driving an astonishing amount foods containing aspartame, which severely alters their T of scientific progress, colloquially known as the quality of life. biology revolution. The advances come at a fortuitous time. Environmental threats are chipping away at the quality of Evozyne delivered an engineered enzyme that greatly life for millions, while new viral illnesses continue to exceeded Takeda's design specifications, which led to an emerge and thousands of known diseases lack effective initial multi-asset licensing agreement worth up to $400 treatments. million plus potential royalties from any commercial product resulting from the collaboration. Our technology Evozyne, founded by Paragon Biosciences, was created outperformed expectations in this critical test and resulted on the premise that the new-found ability to create high- in an important collaboration for both companies. We are performance proteins can deliver solutions to the some of hopeful this partnership with Takeda will lead to new most intractable modern problems. The company believes treatments that significantly improve the quality of life for that by learning from evolution, it is possible to engineer patients. future-proofed interventions for patients and address environmental challenges in carbon capture and energy What are the primary objectives and philosophy of storage. Evozyne? To learn more about its biology-based advancements, we at We believe boundary-breaking biology is the key to Insights Success crossed paths with Evozyne's team, and in transformational applications in therapeutics and the following interview, the company outlines its sustainability. Understanding that nature is the original and pathbreaking vision to benefit humanity. best engineer, we use deep evolutionary learning in the lab to understand millions of years of evolution. Below are the highlights of the interview. By using evolution-based design, we're able to tackle some What was the initial idea behind the inception of of society's biggest challenges, like finding treatments for Evozyne? patients with untreated diseases and developing solutions for sustainability concerns. Evozyne was founded by Paragon Biosciences to advance boundary-breaking biology from the laboratory and into the Philosophically, we are highly pragmatic and our design- therapeutics. From a timeline point of function in the conditions real world, where it can solve complex problems. build-test approach is applied to every aspect of our work. view, Evozyne works from the earliest points, associated with power generation. Believing that the engineered proteins will dramatically We partner with like-minded entities, working together to identifying and optimizing lead targets, and continues its accelerate scientific breakthroughs, in two years we find world-changing solutions. work through developing experimental therapeutics and Our tests indicate that we have a product that meets the recruited a world-class team of nearly 100 computational supporting them through Phase 3 clinical trials. challenge of enzymatic on-site carbon capture, which scientists, researchers, and commercial leaders to conduct a To realize the impact and potential of our engineered means if successful the CO from power generation is never series of validation projects from Evozyne's new 30,000- proteins, we need partners who share our vision for a better 2 Currently, we are creating high-performance enzymes for released into the atmosphere. We look forward to proving square-foot lab in Chicago. world and a commitment to the breakthrough approaches our partners at Takeda and developing antibody, gene its performance, first at the University of Kentucky this year required to get there. Our next-generation proteins can be optimization, and CRISPR technology platforms that we and later at the National Carbon Capture Center in Evozyne's evolution-based design is about encapsulating tailored across functions, and our efficient design-build-test believe will lead to the development of breakthrough Alabama. vital information from the evolutionary history of a protein cycles enable commercial-scale solutions that unlock new therapeutics for patients. into a computationally defined latent space that enables products and IP for our partners. What are the roadblocks that Evozyne faces in the ever- rational design of natural-like proteins. When combined On the sustainability side, protein engineering moves the changing landscape of the business world? with an iterative design-build-test approach, the models What are your key offerings that have a foothold in the science beyond traditional chemical catalysts by developing generate protein designs that far exceed performance of industry? enzymes that can withstand industrial conditions, Science is unpredictable, and it's hard. Those two facts, plus natural proteins and can be deployed in in real-world functioning in high-temperature conditions, and the competitive nature of biotech businesses, make it applications. Evozyne began by combining artificial intelligence, overcoming pH resistance. tempting to rush products to market. There are notable specifically machine learning, with applied biology to examples of synthetic biology companies that gave in to In an early project, Evozyne partnered with Takeda, the accelerate scientific discovery. The process speeds up lead Our lead sustainability candidate is engineered to perform that temptation, sold products that didn't perform as billed Japanese pharmaceutical company, to improve the identification for new medicines, which can result in at temperatures above 260 degrees Fahrenheit in an and subsequently failed. therapeutic potential of a specific target to treat a severe findings that support investigational new drug applications industrial setting. Until now, no enzyme has been able to genetic disease. This inherited disorder causes a dangerous and biologic license applications for experimental

14. Evozyne followed those stories closely, and our team is How is your company adapting to market orientation? space is impossibly large—much larger than the number of Using our computational biology approach, we engineer committed to doing things differently. Our highly atoms in the known universe—and no existing approach transgenes with superior performance in activity, affinity, pragmatic, design/built/test model requires us to repeatedly Nearly half of the world's disease burden will be addressed can comprehensively search it. stability, and immunogenicity. In addition, Evozyne's prove to ourselves, with objective data, that the technology by biology in the next 20 years. With that in mind, we're technology enables miniaturization of the gene cassette, performs as expected in real-world conditions. Evozyne pursuing life-changing treatments for patients and finding Yet that's where we believe we'll find answers to the world's unlocking cures for previously inaccessible diseases. will bring products to market when and if they are proven ways to improve life for patients with diseases that aren't most pressing scientific questions. Gene editing with CRISPR-Cas nucleases has introduced to a high level of certainty. currently treatable. There are more than 10,000 diseases for new therapeutic modalities to treat a wide range of diseases. which no medicine exists, and we hope to be part of the Our machine learning models help us find evolvable Yet the existing nucleases are not specific enough and can Being first can be a disadvantage if you fail to meet market solution for patients who lack options. proteins from that vast space that can be engineered to meet cause off-target editing, which means they edit the genome expectations. Protecting our reputation is a top priority for real world challenges. More importantly, we learn from in areas that are not intended. Evozyne, and that means making sure we've done the hard On the sustainability side, we're working to address climate every sequence generated in the design process, not just work to prove the performance of our technology platforms. change with an on-site solution for carbon capture. We're from the ones that work. By augmenting and redesigning the nucleases created by uncovering new paths to replace harmful plastics and nature, Evozyne is developing a comprehensive library of Beyond reputation management, recruiting top scientific addressing global warming by making carbon capture a Evozyne generates genotype-phenotype mapping for every highly specific Cas nucleases that can access most of the talent is a hurdle for many biotech companies. Fortunately, reality. Our goal is to build high-performance proteins, with sequence generated, adding to our libraries and ability to genome. This combination of accessibility and specificity Evozyne has proven its ability to hire top talent, which we exceptionally advanced functionality that makes what's find desired solutions faster. The design rules uncovered will allow previously untreatable diseases to be cured safely attribute to our pragmatic approach, the impact of the possible a reality. They are designed to be consistent with from these sequences help us simultaneously optimize and effectively with our enzymes. problems we're working to solve, and the financial health of the laws of nature and match the complex character of several protein functions. That's a whole lot more efficient our company. It helps that Chicago is a world-class city, natural environments, enabling biology-based solutions that than optimizing one property at a time. The Pandemic provided another complex problem that we with globally renowned universities and a thriving open our imagination to what's possible in solving some of hope to solve. We all know that as viruses mutate, they ecosystem that supports emerging biotech and pharma society's most intractable problems. This functional innovation forms our design philosophy, develop resistance to antibodies, rendering therapeutics companies. The scientific talent we need to succeed wants unlocking the natural potential of evolved proteins. ineffective. The problem treating viral infection is one of to work here and, more What is your approach to implementing innovative understanding the evolvability of the virus. Despite important, is happy technologies? How does your company provide a societal benefit? widespread research, current discovery tools have limited living here. success in countering viral resistance. It's important to understand We're using science to solve some of the most complex that the protein sequence problems our society faces. Using our ability to understand the constraints on viral evolution, Evozyne is developing an approach to generate Think about it like this. Our platform is capable of creating future-proofed, broadly neutralizing antibodies. Our first molecules that surpass the current limits of performance. application of this platform is a variant-resistant COVID-19 We can achieve targeted improvements in function that antibody. mirrors the capabilities of natural evolution. If nature is the world's best engineer, imagine what it can do if it's fast- Evozyne's sustainability practice is focused on carbon forwarded by a few million years. capture and battery technology. What is the next chapter for Evozyne? Capturing carbon at the point of production has been inefficient and energy-intensive. Right now, it's too Our focus is on developing technology platforms for expensive to reduce emissions. While naturally occurring therapeutics and sustainability. On the therapeutics side, the solutions can improve efficiency, they cannot withstand focus is on gene optimization, gene editing, and future- harsh industrial conditions and can't perform at high proofed antibodies. temperatures. Gene replacement therapy requires better-than-wildtype Leveraging design rules encoded by nature, Evozyne is performing genes to minimize dosing, maximize efficacy, developing a highly efficient organic catalyst that remains and reduce immunogenicity. Existing gene therapies are not stable in the required industrial conditions, making carbon simultaneously optimized across all these dimensions. capture at the point of production cost-effective. Furthermore, certain diseases require replacement of genes that are too large to fit into existing delivery technologies, rendering them inaccessible.

15. Evozyne followed those stories closely, and our team is How is your company adapting to market orientation? space is impossibly large—much larger than the number of Using our computational biology approach, we engineer committed to doing things differently. Our highly atoms in the known universe—and no existing approach transgenes with superior performance in activity, affinity, pragmatic, design/built/test model requires us to repeatedly Nearly half of the world's disease burden will be addressed can comprehensively search it. stability, and immunogenicity. In addition, Evozyne's prove to ourselves, with objective data, that the technology by biology in the next 20 years. With that in mind, we're technology enables miniaturization of the gene cassette, performs as expected in real-world conditions. Evozyne pursuing life-changing treatments for patients and finding Yet that's where we believe we'll find answers to the world's unlocking cures for previously inaccessible diseases. will bring products to market when and if they are proven ways to improve life for patients with diseases that aren't most pressing scientific questions. Gene editing with CRISPR-Cas nucleases has introduced to a high level of certainty. currently treatable. There are more than 10,000 diseases for new therapeutic modalities to treat a wide range of diseases. which no medicine exists, and we hope to be part of the Our machine learning models help us find evolvable Yet the existing nucleases are not specific enough and can Being first can be a disadvantage if you fail to meet market solution for patients who lack options. proteins from that vast space that can be engineered to meet cause off-target editing, which means they edit the genome expectations. Protecting our reputation is a top priority for real world challenges. More importantly, we learn from in areas that are not intended. Evozyne, and that means making sure we've done the hard On the sustainability side, we're working to address climate every sequence generated in the design process, not just work to prove the performance of our technology platforms. change with an on-site solution for carbon capture. We're from the ones that work. By augmenting and redesigning the nucleases created by uncovering new paths to replace harmful plastics and nature, Evozyne is developing a comprehensive library of Beyond reputation management, recruiting top scientific addressing global warming by making carbon capture a Evozyne generates genotype-phenotype mapping for every highly specific Cas nucleases that can access most of the talent is a hurdle for many biotech companies. Fortunately, reality. Our goal is to build high-performance proteins, with sequence generated, adding to our libraries and ability to genome. This combination of accessibility and specificity Evozyne has proven its ability to hire top talent, which we exceptionally advanced functionality that makes what's find desired solutions faster. The design rules uncovered will allow previously untreatable diseases to be cured safely attribute to our pragmatic approach, the impact of the possible a reality. They are designed to be consistent with from these sequences help us simultaneously optimize and effectively with our enzymes. problems we're working to solve, and the financial health of the laws of nature and match the complex character of several protein functions. That's a whole lot more efficient our company. It helps that Chicago is a world-class city, natural environments, enabling biology-based solutions that than optimizing one property at a time. The Pandemic provided another complex problem that we with globally renowned universities and a thriving open our imagination to what's possible in solving some of hope to solve. We all know that as viruses mutate, they ecosystem that supports emerging biotech and pharma society's most intractable problems. This functional innovation forms our design philosophy, develop resistance to antibodies, rendering therapeutics companies. The scientific talent we need to succeed wants unlocking the natural potential of evolved proteins. ineffective. The problem treating viral infection is one of to work here and, more What is your approach to implementing innovative understanding the evolvability of the virus. Despite important, is happy technologies? How does your company provide a societal benefit? widespread research, current discovery tools have limited living here. success in countering viral resistance. It's important to understand We're using science to solve some of the most complex that the protein sequence problems our society faces. Using our ability to understand the constraints on viral evolution, Evozyne is developing an approach to generate Think about it like this. Our platform is capable of creating future-proofed, broadly neutralizing antibodies. Our first molecules that surpass the current limits of performance. application of this platform is a variant-resistant COVID-19 We can achieve targeted improvements in function that antibody. mirrors the capabilities of natural evolution. If nature is the world's best engineer, imagine what it can do if it's fast- Evozyne's sustainability practice is focused on carbon forwarded by a few million years. capture and battery technology. What is the next chapter for Evozyne? Capturing carbon at the point of production has been inefficient and energy-intensive. Right now, it's too Our focus is on developing technology platforms for expensive to reduce emissions. While naturally occurring therapeutics and sustainability. On the therapeutics side, the solutions can improve efficiency, they cannot withstand focus is on gene optimization, gene editing, and future- harsh industrial conditions and can't perform at high proofed antibodies. temperatures. Gene replacement therapy requires better-than-wildtype Leveraging design rules encoded by nature, Evozyne is performing genes to minimize dosing, maximize efficacy, developing a highly efficient organic catalyst that remains and reduce immunogenicity. Existing gene therapies are not stable in the required industrial conditions, making carbon simultaneously optimized across all these dimensions. capture at the point of production cost-effective. Furthermore, certain diseases require replacement of genes that are too large to fit into existing delivery technologies, rendering them inaccessible.

18. The 10 Most Emerging Biotech Companies To Watch in 2022 October 2022 | 16 | www.insightssuccess.com October 2022 | 17 | www.insightssuccess.com

19. The 10 Most Emerging Biotech Companies To Watch in 2022 October 2022 | 16 | www.insightssuccess.com October 2022 | 17 | www.insightssuccess.com

20. October 2022 | 18 | www.insightssuccess.com October 2022 | 19 | www.insightssuccess.com

21. October 2022 | 18 | www.insightssuccess.com October 2022 | 19 | www.insightssuccess.com

22. The 10 Most Emerging Biotech Companies To Watch in 2022 October 2022 | 20 | www.insightssuccess.com October 2022 | 21 | www.insightssuccess.com

23. The 10 Most Emerging Biotech Companies To Watch in 2022 October 2022 | 20 | www.insightssuccess.com October 2022 | 21 | www.insightssuccess.com

24. The 10 Most Emerging Biotech Companies To Watch in 2022 October 2022 | 22 | www.insightssuccess.com October 2022 | 23 | www.insightssuccess.com

25. The 10 Most Emerging Biotech Companies To Watch in 2022 October 2022 | 22 | www.insightssuccess.com October 2022 | 23 | www.insightssuccess.com

28. October 2022 | 26 | www.insightssuccess.com October 2022 | 27 | www.insightssuccess.com

29. October 2022 | 26 | www.insightssuccess.com October 2022 | 27 | www.insightssuccess.com

30. The 10 Most Emerging Biotech Companies To Watch in 2022 October 2022 | 28 | www.insightssuccess.com October 2022 | 29 | www.insightssuccess.com

31. The 10 Most Emerging Biotech Companies To Watch in 2022 October 2022 | 28 | www.insightssuccess.com October 2022 | 29 | www.insightssuccess.com

32. October 2022 | 30 | www.insightssuccess.com October 2022 | 31 | www.insightssuccess.com

33. October 2022 | 30 | www.insightssuccess.com October 2022 | 31 | www.insightssuccess.com

34. October 2022 | 32 | www.insightssuccess.com October 2022 | 33 | www.insightssuccess.com

35. October 2022 | 32 | www.insightssuccess.com October 2022 | 33 | www.insightssuccess.com

38. The 10 Most Emerging Biotech Companies To Watch in 2022 October 2022 | 36 | www.insightssuccess.com October 2022 | 37 | www.insightssuccess.com

39. The 10 Most Emerging Biotech Companies To Watch in 2022 October 2022 | 36 | www.insightssuccess.com October 2022 | 37 | www.insightssuccess.com

40. The 10 Most Emerging Biotech Companies To Watch in 2022 October 2022 | 38 | www.insightssuccess.com October 2022 | 39 | www.insightssuccess.com

41. The 10 Most Emerging Biotech Companies To Watch in 2022 October 2022 | 38 | www.insightssuccess.com October 2022 | 39 | www.insightssuccess.com

42. The 10 Most Emerging Biotech Companies To Watch in 2022 October 2022 | 40 | www.insightssuccess.com October 2022 | 41 | www.insightssuccess.com

43. The 10 Most Emerging Biotech Companies To Watch in 2022 October 2022 | 40 | www.insightssuccess.com October 2022 | 41 | www.insightssuccess.com